Literature DB >> 22659408

Glycine release is regulated by metabotropic glutamate receptors sensitive to mGluR2/3 ligands and activated by N-acetylaspartylglutamate (NAAG).

Cristina Romei1, Maurizio Raiteri, Luca Raiteri.   

Abstract

The presence of metabotropic glutamate receptors (mGluRs) of group II modulating glycine exocytosis from glycinergic nerve endings of mouse spinal cord was investigated. Purified synaptosomes were selectively prelabeled with [(3)H]glycine through the neuronal transporter GlyT2 and subsequently depolarized by superfusion with 12 mM KCl. The selective mGluR2/3 agonist LY379268 inhibited the K(+)-evoked overflow of [(3)H]glycine in a concentration-dependent manner (EC(50) about 0.2 nM). The effect of LY379268 was prevented by the selective mGluR2/3 antagonist LY341495 (IC(50) about 1 nM). N-acetylaspartylglutamate (NAAG) inhibited [(3)H]glycine overflow with extraordinary potency (EC(50) about 50 fmol). In contrast, glutamate was ineffective up to 0.1 nM, excluding that glutamate contamination of commercial NAAG samples is responsible for the reported activity of NAAG at mGluR3. LY341495 antagonized the NAAG inhibition of [(3)H]glycine release. The effect of a combination of maximally effective concentrations of LY379268 and NAAG exhibited no additivity. The non-hydrolysable NAAG analogue N-acetylaspartyl-β-linked glutamate (β-NAAG) antagonized NAAG and LY379268. In conclusion, our results show that glycinergic nerve endings in spinal cord are endowed with group II mGluRs mediating inhibition of glycine exocytosis. NAAG can activate these presynaptic receptors with extremely high affinity and with characteristics compatible with the reported mGluR3 pharmacology. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659408     DOI: 10.1016/j.neuropharm.2012.05.030

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

Review 1.  A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition.

Authors:  Joseph H Neale; Rafal Olszewski
Journal:  Neurobiol Learn Mem       Date:  2019-01-07       Impact factor: 2.877

2.  Contribution of opioid and metabotropic glutamate receptor mechanisms to inhibition of bladder overactivity by tibial nerve stimulation.

Authors:  Yosuke Matsuta; Abhijith D Mally; Fan Zhang; Bing Shen; Jicheng Wang; James R Roppolo; William C de Groat; Changfeng Tai
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-10       Impact factor: 3.619

Review 3.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

4.  Presynaptic, release-regulating mGlu2 -preferring and mGlu3 -preferring autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating disease.

Authors:  Silvia Di Prisco; Elisa Merega; Tommaso Bonfiglio; Guendalina Olivero; Chiara Cervetto; Massimo Grilli; Cesare Usai; Mario Marchi; Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2016-03-03       Impact factor: 8.739

5.  Immuno-pharmacological characterization of group II metabotropic glutamate receptors controlling glutamate exocytosis in mouse cortex and spinal cord.

Authors:  Guendalina Olivero; Tommaso Bonfiglio; Matteo Vergassola; Cesare Usai; Barbara Riozzi; Giuseppe Battaglia; Ferdinando Nicoletti; Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2017-10-29       Impact factor: 8.739

Review 6.  Presynaptic Release-regulating Metabotropic Glutamate Receptors: An Update.

Authors:  Guendalina Olivero; Matteo Vergassola; Francesca Cisani; Alessandra Roggeri; Anna Pittaluga
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

Review 7.  N-Acetyl-Aspartyl-Glutamate in Brain Health and Disease.

Authors:  Cecilie Morland; Kaja Nordengen
Journal:  Int J Mol Sci       Date:  2022-01-23       Impact factor: 5.923

Review 8.  N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation.

Authors:  John R Moffett; Peethambaran Arun; Prasanth S Ariyannur; Aryan M A Namboodiri
Journal:  Front Neuroenergetics       Date:  2013-12-26

9.  NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.

Authors:  Rafal T Olszewski; Karolina J Janczura; Tomasz Bzdega; Elise K Der; Faustino Venzor; Brennen O'Rourke; Timothy J Hark; Kirsten E Craddock; Shankar Balasubramanian; Charbel Moussa; Joseph H Neale
Journal:  Neurochem Res       Date:  2017-03-11       Impact factor: 3.996

Review 10.  Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism.

Authors:  João M N Duarte; Lijing Xin
Journal:  Neurochem Res       Date:  2018-04-03       Impact factor: 3.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.